» Articles » PMID: 30661024

Secondhand Smoke Alters Arachidonic Acid Metabolism and Inflammation in Infants and Children with Cystic Fibrosis

Abstract

Background: Mechanisms that facilitate early infection and inflammation in cystic fibrosis (CF) are unclear. We previously demonstrated that children with CF and parental-reported secondhand smoke exposure (SHSe) have increased susceptibility to bacterial infections. SHSe hinders arachidonic acid (AA) metabolites that mediate immune function in patients without CF, and may influence CF immune dysfunction. We aimed to define SHSe's impact on inflammation mediators and infection in children with CF.

Methods: Seventy-seven children with CF <10 years of age 35 infants <1 year; 42 children 1-10 years) were enrolled and hair nicotine concentrations measured as an objective surrogate of SHSe. AA signalling by serum and macrophage lipidomics, inflammation using blood transcriptional profiles and in vitro macrophage responses to bacterial infection after SHSe were assessed.

Results: Hair nicotine concentrations were elevated in 63% of patients. Of the AA metabolites measured by plasma lipidomics, prostaglandin D (PGD) concentrations were decreased in children with CF exposed to SHSe, and associated with more frequent hospitalisations (p=0.007) and worsened weight z scores (p=0.008). Children with CF exposed to SHSe demonstrated decreased expression of the prostaglandin genes PTGES3 and PTGR2 and overexpression of inflammatory pathways. These findings were confirmed using an in vitro model, where SHSe was associated with a dose-dependent decrease in PGD and increased methicillin-resistant survival in human CF macrophages.

Conclusions: Infants and young children with CF and SHSe have altered AA metabolism and dysregulated inflammatory gene expression resulting in impaired bacterial clearance. Our findings identified potential therapeutic targets to halt early disease progression associated with SHSe in the young population with CF.

Citing Articles

Integrating single-cell RNA-Seq and bulk RNA-Seq data to explore the key role of fatty acid metabolism in hepatocellular carcinoma.

Dai H, Tao X, Shu Y, Liu F, Cheng X, Li X Sci Rep. 2025; 15(1):2077.

PMID: 39814999 PMC: 11735836. DOI: 10.1038/s41598-025-85506-0.


Identification of key metabolism-related genes and pathways in spontaneous preterm birth: combining bioinformatic analysis and machine learning.

Lv W, Xie H, Wu S, Dong J, Jia Y, Ying H Front Endocrinol (Lausanne). 2024; 15:1440436.

PMID: 39229380 PMC: 11368757. DOI: 10.3389/fendo.2024.1440436.


Aconitum coreanum and processed products on its base prevent stroke via the PI3K/Akt and KEAP1/NRF2 in the in vivo study.

Zeng W, Zhou L, Jia R, Liu Y, Cai Q, Qu Y Metab Brain Dis. 2024; 39(5):705-718.

PMID: 38795262 DOI: 10.1007/s11011-024-01357-0.


Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition.

Li X, Suo P, Wang Y, Zou L, Nie X, Zhao Y Front Pharmacol. 2024; 15:1365802.

PMID: 38523633 PMC: 10957658. DOI: 10.3389/fphar.2024.1365802.


A review on the relationship between Arachidonic acid 15-Lipoxygenase (ALOX15) and diabetes mellitus.

He K, Zhou X, Du H, Zhao J, Deng R, Wang J PeerJ. 2023; 11:e16239.

PMID: 37849828 PMC: 10578307. DOI: 10.7717/peerj.16239.


References
1.
Lewis B, Sultana R, Sharma R, Noel A, Langohr I, Patial S . Early Postnatal Secondhand Smoke Exposure Disrupts Bacterial Clearance and Abolishes Immune Responses in Muco-Obstructive Lung Disease. J Immunol. 2017; 199(3):1170-1183. DOI: 10.4049/jimmunol.1700144. View

2.
Freedman S, Blanco P, Zaman M, Shea J, Ollero M, Hopper I . Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med. 2004; 350(6):560-9. DOI: 10.1056/NEJMoa021218. View

3.
Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson C, Robinson P . Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med. 2011; 184(1):75-81. DOI: 10.1164/rccm.201011-1892OC. View

4.
Wojewodka G, De Sanctis J, Bernier J, Berube J, Ahlgren H, Gruber J . Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients. PLoS One. 2014; 9(2):e88567. PMC: 3922941. DOI: 10.1371/journal.pone.0088567. View

5.
Maqbool A, Schall J, Gallagher P, Zemel B, Strandvik B, Stallings V . Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2012; 55(5):605-11. PMC: 4699309. DOI: 10.1097/MPG.0b013e3182618f33. View